科前生物获批一款新兽药注册证书

Core Viewpoint - The approval of the new vaccine by the Ministry of Agriculture and Rural Affairs of the People's Republic of China represents a significant milestone for the company, enhancing its product portfolio and market competitiveness [1] Group 1: Product Development - The company has received approval for its recombinant inactivated vaccine for Porcine Circovirus Type 2 (CH17 strain, suspension culture) as a new veterinary drug [1] - This approval is in accordance with the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] Group 2: Business Impact - The successful approval of the vaccine will diversify the company's product offerings, promoting a multi-faceted business development strategy [1] - The new product is expected to positively influence the company's operational growth and market competitiveness [1]